Hereditary Thrombophilic Factors in Glaucoma.
Summary
Our results suggest that there is no significant difference between the prothrombotic inherited risk factors of glaucomatous and nonglaucomatous subjects.
Abstract
PURPOSE
To evaluate the hereditary thrombophilic factors in patients with primary open-angle glaucoma, exfoliative glaucoma, and exfoliation syndrome and to compare their results with those of healthy control subjects.
MATERIALS AND METHODS
The study included 75 patients [25 patients with primary open-angle glaucoma (group I), 25 patients with exfoliative glaucoma (group II), and 25 patients with exfoliation syndrome (group III)] and 25 healthy control subjects (group IV). Well-known hereditary thrombophilic factors including methylenetetrahydrofolate reductase (MTHFR) gene C677T mutation, prothrombin G20210A mutation, factor V Leiden mutation, activated protein C resistance, protein S, protein C, and antithrombin III activities, and homocysteine levels were measured in venous blood samples of all subjects.
RESULTS
Fifty-one males and 49 females were included in the study. The mean age of the patients was 67.8 ± 8.7 years (range, 46 to 87 y). There was no statistically significant difference with regard to the mean age (P=0.057) and distribution of sex (P=0.391) between the study groups. The difference of homocysteine, folate, vitamin B12, antithrombin III activity, protein C activity, free protein S activity, and activated protein C resistance were not statistically significant; and the number of subjects with MTHFR C677T, prothrombin G20210A, and factor V Leiden mutations were similar between the study groups.
CONCLUSION
Our results suggest that there is no significant difference between the prothrombotic inherited risk factors of glaucomatous and nonglaucomatous subjects.
More by Mehmet A Sekeroglu
View full profile →Top Research in Epidemiology & Genetics
Browse all →The Risks and Benefits of Myopia Control.
Two Phase 3 Clinical Trials Comparing the Safety and Efficacy of Netarsudil to Timolol in Patients With Elevated Intraocular Pressure: Rho Kinase Elevated IOP Treatment Trial 1 and 2 (ROCKET-1 and ROCKET-2).
Neuroprotective strategies for retinal disease.
Discussion
Comments and discussion will appear here in a future update.